1887
  1. Home
  2. Eurosurveillance
  3. Volume 24, Issue 19, 09/May/2019
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

Background

A steady increase in HIV drug resistance (HIVDR) has been demonstrated globally in individuals initiating first-line antiretroviral therapy (ART). To support effective use of ART and prevent spread of HIVDR, monitoring is essential.

Aim

We piloted a surveillance system for transmitted HIVDR to assess the feasibility of implementation at the European level.

Method

All 31 countries in the European Union and European Economic Area were invited to retrospectively submit data on individuals newly diagnosed with HIV in 2015 who were tested for antiviral susceptibility before ART, either as case-based or as aggregate data. We used the Stanford HIV database algorithm to translate genetic sequences into levels of drug resistance.

Results

Nine countries participated, with six reporting case-based data on 1,680 individuals and four reporting aggregated data on 1,402 cases. Sequence data were available for 1,417 cases: 14.5% of individuals (n = 244) showed resistance to at least one antiretroviral drug. In case-based surveillance, the highest levels of transmitted HIVDR were observed for non-nucleoside reverse-transcriptase inhibitors (NNRTIs) with resistance detected in 8.6% (n = 145), followed by resistance to nucleoside reverse-transcriptase inhibitors (NRTI) (5.1%; n = 85) and protease inhibitors (2.0%; n = 34).

Conclusion

We conclude that standard reporting of HIVDR data was feasible in the participating countries. Legal barriers for data sharing, consensus on definitions and standardisation of interpretation algorithms should be clarified in the process of enhancing European-wide HIV surveillance with drug resistance information.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.19.1800390
2019-05-09
2024-11-24
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.19.1800390
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/19/eurosurv-24-19-3.html?itemId=/content/10.2807/1560-7917.ES.2019.24.19.1800390&mimeType=html&fmt=ahah

References

  1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.  https://doi.org/10.1056/NEJMoa1105243  PMID: 21767103 
  2. Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292-307.  https://doi.org/10.1016/j.meegid.2016.08.031  PMID: 27587334 
  3. World Health Organization (WHO). Global action plan on HIV drug resistance 2017-2021. Geneva: WHO; July 2018. Available from: https://www.who.int/hiv/pub/drugresistance/gap-hivdr-progress2018/en/
  4. European Aids Clinical Society (EACS). EACS guidelines; edition 9.1. Brussels: EACS; 2018. Available from: http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf
  5. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. SPREAD Program. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016;62(5):655-63.  https://doi.org/10.1093/cid/civ963  PMID: 26620652 
  6. Keating P, Pharris A, Leitmeyer K, De Angelis S, Wensing A, Amato-Gauci AJ, et al. Assessment of HIV molecular surveillance capacity in the European Union, 2016. Euro Surveill. 2017;22(49).  https://doi.org/10.2807/1560-7917.ES.2017.22.49.17-00269  PMID: 29233253 
  7. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608-18.  https://doi.org/10.1086/503914  PMID: 16652319 
  8. Stanford University. HIV drug resistance database. The World Health Organization 2009 list of mutations for surveillance of transmitted drug resistance HIV strains. Palo Alto: Stanford University. [Accessed: 10 Nov 2017]. Available from: https://hivdb.stanford.edu/page/who-sdrm-list
  9. Shafer RW, Rhee SY, Bennett DE. Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther. 2008;13(Suppl 2):59-68. PMID: 18575192 
  10. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724.  https://doi.org/10.1371/journal.pone.0004724  PMID: 19266092 
  11. Sasse A, Deblonde J, Jamine D, Cloë O, Van Beckhoven D. National HIV/AIDS surveillance data Belgium, 2016. Brussels: WIV-ISP; 2017.
  12. Hauser A, Hofmann A, Hanke K, Bremer V, Bartmeyer B, Kuecherer C, et al. National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014. Euro Surveill. 2017;22(2):30436.  https://doi.org/10.2807/1560-7917.ES.2017.22.2.30436  PMID: 28105988 
  13. Karlsson A, Björkman P, Bratt G, Ekvall H, Gisslén M, Sönnerborg A, et al. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One. 2012;7(3):e33484.  https://doi.org/10.1371/journal.pone.0033484  PMID: 22448246 
  14. Andersson E, Nordquist A, Esbjörnsson J, Flamholc L, Gisslén M, Hejdeman B, et al. Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden. AIDS. 2018;32(7):877-84.  https://doi.org/10.1097/QAD.0000000000001763  PMID: 29369826 
  15. European Centre for Disease Prevention and Control (ECDC)/World Health Organization Regional Office for Europe. HIV/AIDS surveillance in Europe 2015. Stockholm: ECDC; 2016. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/HIV-AIDS-surveillance-Europe-2015.pdf
Piloting a surveillance system for HIV drug resistance in the European Union
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Marita+JW+van+de+Laar&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van de Laar Marita JW</a>, <a href="/search?value1=Arnold+Bosman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bosman Arnold</a>, <a href="/search?value1=Anastasia+Pharris&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pharris Anastasia</a>, <a href="/search?value1=Emmi+Andersson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Andersson Emmi</a>, <a href="/search?value1=Lambert+Assoumou&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Assoumou Lambert</a>, <a href="/search?value1=Eva+Ay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ay Eva</a>, <a href="/search?value1=Norbert+Bannert&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bannert Norbert</a>, <a href="/search?value1=Barbara+Bartmeyer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bartmeyer Barbara</a>, <a href="/search?value1=Melissa+Brady&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brady Melissa</a>, <a href="/search?value1=Marie-Laure+Chaix&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Chaix Marie-Laure</a>, <a href="/search?value1=Diane+Descamps&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Descamps Diane</a>, <a href="/search?value1=Kenny+Dauwe&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dauwe Kenny</a>, <a href="/search?value1=Jannik+Fonager&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fonager Jannik</a>, <a href="/search?value1=Andrea+Hauser&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hauser Andrea</a>, <a href="/search?value1=Maja+Lunar&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lunar Maja</a>, <a href="/search?value1=Maria+Mezei&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mezei Maria</a>, <a href="/search?value1=Martha+Neary&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Neary Martha</a>, <a href="/search?value1=Mario+Poljak&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Poljak Mario</a>, <a href="/search?value1=Ard+van+Sighem&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van Sighem Ard</a>, <a href="/search?value1=Chris+Verhofstede&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Verhofstede Chris</a>, <a href="/search?value1=Andrew+J+Amato-Gauci&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Amato-Gauci Andrew J</a>, <a href="/search?value1=Eeva+K+Broberg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Broberg Eeva K</a></span>. Piloting a surveillance system for HIV drug resistance in the European Union. <a href="/content/ecdc">Euro Surveill.</a> 2019;24(19):pii=1800390. <a href="https://doi.org/10.2807/1560-7917.ES.2019.24.19.1800390" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2019.24.19.1800390</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 16 Jul 2018;&nbsp;&nbsp; <span class="generated">Accepted</span>: 11 Apr 2019 </span> </p>
/content/10.2807/1560-7917.ES.2019.24.19.1800390
/content/10.2807/1560-7917.ES.2019.24.19.1800390
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error